ReviewJournal of cancer research and clinical oncology2025
Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review.
Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advanced and underlying therapeutic strategies in transformed small cell lung cancer.Frontiers in medicine · 2026Review
- A rare pulmonary epithelioid angiosarcoma with ALK rearrangement: a case report and literature review.Frontiers in oncology · 2026Article
- Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with AdvancedInternational journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeWith the continuous development and progress of next-generation gene sequencing technology, many types of anaplastic lymphoma kinase (ALK) rearrangement have been discovered. However, in small cell lung cancer (SCLC), ALK rearrangement is extremely rare and there is no standard treatment protocol. By reviewing the literature, we summarized the previously reported cases of ALK-positive SCLC, and discussed the significance of molecular detection.
methodWe report a rare patient with EML4-ALK fusion gene SCLC, a 41-year-old woman with no history of smoking or drinking, who was admitted to the hospital with chest tightness, dyspnea, and cough and sputum. Extensive SCLC (cT4N0M1) was diagnosed after relevant examination and pathological examination. The patient relapsed again six months after receiving first-line chemoradiotherapy. And the patient still developed disease progression (PD) after continued multi-line treatment including chemotherapy, immunotherapy, and anti-vascular therapy. ALK inhibitor is currently being taken orally, and significant clinical response has been achieved. Progression-free survival (PFS) was more than 8 months.
resultALK rearrangement of SCLC is rare. The stage IV patient with ALK rearrangement benefit from ALK inhibitors after multiline therapy.
conclusionFor patients with ALK-positive SCLC, ALK inhibitors may be a reliable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.